Morningstar Rates Novo Nordisk (NVO) Stock Heavily Overvalued at 85 Percent Premium as Wegovy Competition Intensifies

Morningstar Rates Novo Nordisk (NVO) Stock Heavily Overvalued at 85 Percent Premium as Wegovy Competition Intensifies

Novo Nordisk A/S (NYSE: NVO) is trading at an 85 percent premium to Morningstar’s fair value estimate of $18.00 per share, with the stock sitting around $40 to $41, making it one of the most starkly overvalued large-cap pharmaceutical names in the research firm’s coverage universe despite the ongoing collapse in NVO’s share price from […] The post Morningstar Rates Novo Nordisk (NVO) Stock Heavily Overvalued at 85 Percent Premium as Wegovy Compe…